Cargando…

H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression

Background and Purpose: Septic cardiomyopathy, which is one of the features of multi-organ dysfunction in sepsis, is characterized by ventricular dilatation, reduced ventricular contractility, and reduction in ejection fraction and, if severe, can lead to death. To date, there is no specific therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Sihua, Long, Zhiyuan, Hou, Xiangping, Lin, Yujie, Xu, Jingting, You, Xinchao, Wang, Tinghuai, Zhang, Yaxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694767/
https://www.ncbi.nlm.nih.gov/pubmed/31440160
http://dx.doi.org/10.3389/fphar.2019.00865
_version_ 1783443897273286656
author Tan, Sihua
Long, Zhiyuan
Hou, Xiangping
Lin, Yujie
Xu, Jingting
You, Xinchao
Wang, Tinghuai
Zhang, Yaxing
author_facet Tan, Sihua
Long, Zhiyuan
Hou, Xiangping
Lin, Yujie
Xu, Jingting
You, Xinchao
Wang, Tinghuai
Zhang, Yaxing
author_sort Tan, Sihua
collection PubMed
description Background and Purpose: Septic cardiomyopathy, which is one of the features of multi-organ dysfunction in sepsis, is characterized by ventricular dilatation, reduced ventricular contractility, and reduction in ejection fraction and, if severe, can lead to death. To date, there is no specific therapy that exists, and its treatment represents a large unmet clinical need. Herein, we investigated the effects and underlying anti-inflammatory mechanisms of hydrogen gas in the setting of lipopolysaccharide (LPS)-induced cardiomyocytes injury. Experimental Approach: Hydrogen gas was intraperitoneally injected to mice in LPS plus hydrogen group and hydrogen group for 4 days. On fourth, LPS was given by intraperitoneal injection to mice in LPS group and to mice in LPS plus hydrogen group. In addition, H9c2 cardiomyocytes were treated with hydrogen-rich medium for 30 min before LPS. The transthoracic echocardiography was performed at 6 h post‐LPS to assess left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (EF%), fractional shortening (FS%), left ventricular mass average weight (LV mass AW), and LV mass AW (Corrected). The histological and morphological analyses of left ventricular were performed by hematoxylin and eosin (H&E) staining and Masson’s trichrome staining. The mRNA levels of ANP and BNP were examined by PCR in vitro. The expression of cytokines were assayed by Enzyme Linked Immunosorbent Assay (ELISA) and PCR. Moreover, Western blotting was performed to examine the expression of TLR4, the activation of ERK1/2, p38, JNK, and the expression of NF-κB in nucleus after 6 h of LPS challenge in vivo and in vitro. Key Results: LPS induced cardiac dysfunction; hydrogen therapy improved cardiac function after LPS challenge. Furthermore, pretreatment with hydrogen resulted in cardioprotection during septic cardiomyopathy via inhibiting the expression of pro-inflammatory cytokines TNFα, IL-1β, and IL-18; suppressing the phosphorylation of ERK1/2, p38, and JNK; and reducing the nuclear translocation of NF-κB and the expression of TLR4 by LPS. Conclusion and Implications: Hydrogen therapy prevents LPS-induced cardiac dysfunction in part via downregulation of TLR4-mediated pro-inflammatory cytokines expression.
format Online
Article
Text
id pubmed-6694767
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66947672019-08-22 H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression Tan, Sihua Long, Zhiyuan Hou, Xiangping Lin, Yujie Xu, Jingting You, Xinchao Wang, Tinghuai Zhang, Yaxing Front Pharmacol Pharmacology Background and Purpose: Septic cardiomyopathy, which is one of the features of multi-organ dysfunction in sepsis, is characterized by ventricular dilatation, reduced ventricular contractility, and reduction in ejection fraction and, if severe, can lead to death. To date, there is no specific therapy that exists, and its treatment represents a large unmet clinical need. Herein, we investigated the effects and underlying anti-inflammatory mechanisms of hydrogen gas in the setting of lipopolysaccharide (LPS)-induced cardiomyocytes injury. Experimental Approach: Hydrogen gas was intraperitoneally injected to mice in LPS plus hydrogen group and hydrogen group for 4 days. On fourth, LPS was given by intraperitoneal injection to mice in LPS group and to mice in LPS plus hydrogen group. In addition, H9c2 cardiomyocytes were treated with hydrogen-rich medium for 30 min before LPS. The transthoracic echocardiography was performed at 6 h post‐LPS to assess left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (EF%), fractional shortening (FS%), left ventricular mass average weight (LV mass AW), and LV mass AW (Corrected). The histological and morphological analyses of left ventricular were performed by hematoxylin and eosin (H&E) staining and Masson’s trichrome staining. The mRNA levels of ANP and BNP were examined by PCR in vitro. The expression of cytokines were assayed by Enzyme Linked Immunosorbent Assay (ELISA) and PCR. Moreover, Western blotting was performed to examine the expression of TLR4, the activation of ERK1/2, p38, JNK, and the expression of NF-κB in nucleus after 6 h of LPS challenge in vivo and in vitro. Key Results: LPS induced cardiac dysfunction; hydrogen therapy improved cardiac function after LPS challenge. Furthermore, pretreatment with hydrogen resulted in cardioprotection during septic cardiomyopathy via inhibiting the expression of pro-inflammatory cytokines TNFα, IL-1β, and IL-18; suppressing the phosphorylation of ERK1/2, p38, and JNK; and reducing the nuclear translocation of NF-κB and the expression of TLR4 by LPS. Conclusion and Implications: Hydrogen therapy prevents LPS-induced cardiac dysfunction in part via downregulation of TLR4-mediated pro-inflammatory cytokines expression. Frontiers Media S.A. 2019-08-05 /pmc/articles/PMC6694767/ /pubmed/31440160 http://dx.doi.org/10.3389/fphar.2019.00865 Text en Copyright © 2019 Tan, Long, Hou, Lin, Xu, You, Wang and Zhang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Tan, Sihua
Long, Zhiyuan
Hou, Xiangping
Lin, Yujie
Xu, Jingting
You, Xinchao
Wang, Tinghuai
Zhang, Yaxing
H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression
title H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression
title_full H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression
title_fullStr H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression
title_full_unstemmed H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression
title_short H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression
title_sort h(2) protects against lipopolysaccharide-induced cardiac dysfunction via blocking tlr4-mediated cytokines expression
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694767/
https://www.ncbi.nlm.nih.gov/pubmed/31440160
http://dx.doi.org/10.3389/fphar.2019.00865
work_keys_str_mv AT tansihua h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression
AT longzhiyuan h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression
AT houxiangping h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression
AT linyujie h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression
AT xujingting h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression
AT youxinchao h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression
AT wangtinghuai h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression
AT zhangyaxing h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression